《大行报告》麦格理下调新秀丽(01910.HK)目标价至19元 评级「跑赢大市」
麦格理发表报告表示,新秀丽(01910.HK)首季净销售按年下跌41%至3.55亿美元,经营亏损为4,700万美元,较去年第四季之1.23亿美元亏损有所改善,亦符合该行预期。公司管理层预期,今年第二季销售将较2019年同期跌53%至54%,而下半年则较2019年同期跌30%至40%,意味下半年业务料进一步改善。
该行对新秀丽2021至2023年度经调整盈利预测由亏损5,000万美元/盈利1.25亿美元/盈利1.54亿美元,下调为亏损6,500万美元/盈利1.07亿美元/盈利1.35亿美元,目标价相应由21.6元降至19元,维持「跑赢大市」评级。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.